
Adamas Pharmaceuticals, Inc. ADMS
Adamas Pharmaceuticals, Inc. ROCE | ADMS
ROCE Jährlich Adamas Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -51.86 | -68.22 | -54.63 | -51.85 | -45.95 | -49.12 | 12.46 | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 12.46 | -68.22 | -44.17 |
ROCE anderer Aktien in der Pharmaeinzelhändler
| Name | ROCE | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Alterity Therapeutics Limited
ATHE
|
-104.38 | $ 2.3 | -5.35 % | $ 14.7 B | ||
|
Shineco, Inc.
TYHT
|
-8.2 | - | -3.90 % | $ 97.2 M | ||
|
Millendo Therapeutics, Inc.
MLND
|
-101.55 | - | -5.36 % | $ 20.2 M | ||
|
Certara
CERT
|
1.5 | $ 12.21 | -0.08 % | $ 1.96 B | ||
|
Dyadic International
DYAI
|
-583.64 | $ 0.39 | 1.16 % | $ 14.1 M | ||
|
Intec Pharma Ltd
NTEC
|
-88.86 | - | -12.45 % | $ 17.7 M | ||
|
Anika Therapeutics
ANIK
|
-7.7 | $ 13.42 | -7.89 % | $ 192 M | ||
|
Aprea Therapeutics
APRE
|
-106.37 | $ 0.45 | -9.44 % | $ 2.94 M | ||
|
Galectin Therapeutics
GALT
|
15.7 | $ 3.4 | -1.73 % | $ 217 M | ||
|
Corcept Therapeutics Incorporated
CORT
|
6.68 | $ 73.22 | -2.41 % | $ 7.6 B | ||
|
Progenity, Inc.
PROG
|
-238.7 | - | -3.47 % | $ 164 M | ||
|
Genprex
GNPX
|
-194.87 | $ 2.1 | 1.94 % | $ 1.96 M | ||
|
Strongbridge Biopharma plc
SBBP
|
-43.18 | - | 1.52 % | $ 136 M | ||
|
Innate Pharma S.A.
IPHA
|
-207.17 | $ 1.54 | 1.98 % | $ 138 M | ||
|
Seneca Biopharma, Inc.
SNCA
|
-108.46 | - | -1.19 % | $ 28.7 M | ||
|
BioMarin Pharmaceutical
BMRN
|
5.99 | $ 57.1 | -0.14 % | $ 11 B | ||
|
Matinas BioPharma Holdings
MTNB
|
-121.15 | $ 1.19 | -4.03 % | $ 6.51 M | ||
|
Enanta Pharmaceuticals
ENTA
|
-131.88 | $ 11.24 | -2.01 % | $ 240 K | ||
|
SIGA Technologies
SIGA
|
11.76 | $ 3.14 | -3.83 % | $ 225 M | ||
|
Milestone Pharmaceuticals
MIST
|
-148.77 | $ 0.68 | -7.49 % | $ 72.2 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
12.37 | $ 94.9 | -3.91 % | $ 7.04 B | ||
|
Lipocine
LPCN
|
-71.64 | $ 1.59 | -7.85 % | $ 8.66 M | ||
|
PTC Therapeutics
PTCT
|
44.91 | $ 64.12 | -1.4 % | $ 5.1 B | ||
|
Seres Therapeutics
MCRB
|
-79.05 | $ 1.55 | -8.75 % | $ 13.7 M | ||
|
Madrigal Pharmaceuticals
MDGL
|
-31.61 | $ 432.48 | -0.07 % | $ 9.7 B | ||
|
CEL-SCI Corporation
CVM
|
-155.48 | $ 1.41 | 4.07 % | $ 11.3 M | ||
|
Inventiva S.A.
IVA
|
5530.5 | $ 3.95 | 2.73 % | $ 236 M | ||
|
MeiraGTx Holdings plc
MGTX
|
1829.24 | $ 9.62 | 1.37 % | $ 774 M | ||
|
Processa Pharmaceuticals
PCSA
|
-250.81 | $ 1.86 | -4.62 % | $ 2.44 M | ||
|
Eton Pharmaceuticals
ETON
|
-1.57 | $ 67.5 | 4.9 % | $ 1.82 B | ||
|
IDEAYA Biosciences
IDYA
|
-15.17 | $ 31.72 | -0.97 % | $ 2.81 B | ||
|
Protalix BioTherapeutics
PLX
|
-9.85 | $ 2.86 | 11.28 % | $ 225 M | ||
|
Lantern Pharma
LTRN
|
-275.14 | $ 0.47 | -22.86 % | $ 5.12 M | ||
|
Foghorn Therapeutics
FHTX
|
-62.44 | $ 1.89 | -7.35 % | $ 119 M | ||
|
Ocugen
OCGN
|
-307.31 | $ 0.95 | -2.45 % | $ 297 M | ||
|
Oncolytics Biotech
ONCY
|
-584.69 | $ 0.38 | -5.64 % | $ 36.4 M | ||
|
Minerva Neurosciences
NERV
|
-16.65 | $ 2.47 | -6.08 % | $ 20.9 M | ||
|
Kamada Ltd.
KMDA
|
7.92 | $ 8.09 | 4.93 % | $ 466 M | ||
|
Neurocrine Biosciences
NBIX
|
15.92 | $ 169.08 | 0.13 % | $ 16.8 B | ||
|
Nanobiotix S.A.
NBTX
|
-105.52 | $ 32.8 | 2.4 % | $ 1.57 T | ||
|
Mereo BioPharma Group plc
MREO
|
-68.72 | $ 0.3 | 1.66 % | $ 239 M | ||
|
Maravai LifeSciences Holdings
MRVI
|
-38.08 | $ 7.86 | -2.31 % | $ 1.13 B | ||
|
Lexicon Pharmaceuticals
LXRX
|
-29.8 | $ 1.84 | 0.82 % | $ 668 M | ||
|
Moleculin Biotech
MBRX
|
-167.29 | $ 8.01 | -7.51 % | $ 9.49 M | ||
|
Nurix Therapeutics
NRIX
|
-53.02 | $ 15.89 | -1.58 % | $ 1.38 B | ||
|
Nkarta
NKTX
|
-31.94 | $ 1.36 | -14.78 % | $ 101 M | ||
|
MacroGenics
MGNX
|
-131.03 | $ 2.42 | 3.42 % | $ 153 M | ||
|
Protagonist Therapeutics
PTGX
|
-25.39 | $ 136.18 | 0.2 % | $ 8.66 B | ||
|
Nuvation Bio
NUVB
|
-41.57 | $ 4.22 | -3.1 % | $ 1.44 B | ||
|
Novo Nordisk A/S
NVO
|
39.01 | $ 40.6 | -1.88 % | $ 180 B |